Aldo Caltavituro
@ACaltavituro
Followers
72
Following
537
Media
8
Statuses
37
📢 Our network meta-analysis has just been published in eClinicalMedicine! ✨ 📊 28 RCTs (n=6,544) on systemic therapies after progression on CDK4/6i in HR+/HER2− MBC. 🔍 Targeted agents + ET / SERDs 🧬 💉 ADCs in endocrine-resistant disease 🚀 🙏 Thanks to @CarmineDeA1 and
3
10
38
📢 Just out on @CROH our Italian Delphi consensus 🤝🏻on the evolving landscape of HR+/HER2- mBC (EVOLVE). 💊Resistance/sensitivity to CDK4/6i+ET 🧬Biomarkers 🔎Treatment algorithm 📃: https://t.co/LiAwSn8yDn Proud to be part of this huge national effort.
0
13
28
Thanks to @matteolambe for two amazing days in Genova for #YBO. Outstanding presentations 📚 Lots of friends 👨🏼🔬🧑🔬🧑🏫 Inspiring networking 🔗
1
5
17
Excellent review of post CDK4/6i tx in challenging scenarios. A must read for all breast oncologists! Congrats to @RobertoBuonaiu3, @CarmineDeA1 and all co-authors.
New paper published in Cancer Treatment Reviews! What to consider after progression on CDK4/6i in HR+/HER2- mBC? Insights from a panel of Italian experts. Grateful for the opportunity to contribute to this work! 👉 Open access: https://t.co/T9TmaGbtkM
0
2
5
Terrifying poster presentations at #esmobreast2025 lead my brilliant friends. 1️⃣@RobertoBuonaiu3 💊 2️⃣@alessandralongobardi 🪜 3️⃣@rossanadirienzo 🤖 4️⃣@giuseppedigrazia 📈 @myESMO
0
1
10
So proud of you! @RobertoBuonaiu3
Proud to have shared our work on the comparative analysis of clinical vs AI decision-making in early-stage HR+/HER2- breast cancer as a poster presentation at #SABCS2024. Key findings: •Genomic testing was recommended for all patients (n=380), with Oncotype DX® as the only
0
0
2
📢 Just out in @CHematology our original review: 💊 Warming-up the immune cell engagers (ICEs) era in breast cancer: state of the art and future directions Sincere thanks to @RobertoBuonaiu3, @FedericaMartor5 and all co-authors for huge effort. 📍 https://t.co/Pnd3kGD5hT
0
0
0
⚡️Just out in @TheBreastOnline our work investigating the influence of ethnicity on the efficacy and toxicity of CDK4/6i in HR+/HER2- mBC. 🙏🏻 Grateful to @RobertoBuonaiu3 for the opportunity. 👌Thanks to all co-authors. 🔎To read more:
Thrilled to share our latest study, published in The Breast "Influence of Ethnicity on Cyclin-Dependent Kinase Inhibitor Efficacy and Toxicity: A Systematic Review and Meta-Analysis" 🌟 Focus: Exploring how ethnicity affects the efficacy and toxicity of CDK4/6i in HR+/HER2- mBC
0
0
6
Comprehensive and interesting narrative review about the role and the potential clinical implications of DLL3 in different neuroendocrine neoplasms led by @Drammarita (last photo for matched outfit 🔥) https://t.co/XKwVmg1Uy7
0
0
7
Two amazing day at GIM 2024. 🔥🍀 Happy to be part of this fantastic group.
Si chiudono i lavori delle due stimolanti giornate di congresso GIM 2024 a Udine. Un ringraziamento ai partecipanti e a tutti i relatori. In foto: Proff. Saverio Cinieri, Michelino De Laurentiis, Lucia Del Mastro, Fabio Puglisi, Mario Giuliano, Grazia Arpino, Dott. Pietro De
0
1
9
Does the type of BRCA domain defects influence PARPi efficacy in HGSOC advanced pts? The answer just published in @FrontOncology 🔥 Congrats @RobertoBuonaiu3 and @NeolaGiuseppe and all co-authors!
Insights on PARPi in adv HGSOC: efficacy independent of BRCA domain defects or mutation types. Numerically longer mPFS in pts with DBD defects. Check our new study in @FrontOncology! #OvarianCancer #PARPinhibitors Thanks to @CarmineDeA1 and all co-authors. https://t.co/HVtAHxdijN
0
0
5
Just spent 3 incredibile days in Berlin 🇩🇪 at #ESMOBreast24. Special thanks to my friend and collegue @RobertoBuonaiu3 who gives me the opportunity to present our work on the influence of ethnicity 🌍 on the efficacy and toxicity profile of CDK4/6i in mBC pts. It was amazing🔥
0
1
3
Can't wait to see our poster presentation? See you in Berlin 🇩🇪. @RobertoBuonaiu3
@myESMO #ESMOBreast2024
1
1
12
The limbo of having ER/PR low (<10%) is currently a very important problem for trial enrollment #BCSM #MBC ER 0 PR 5% HER2 0 1⃣cannot be enrolled in HR+ cohorts if have not received CDK4/6i 2⃣cannot be enrolled in TNBC cohort because ASCO/CAP guidelines @FDAOncology relax I/E cr
3
14
49
Does chemotherapy relative dose intensity (RDI) impact on pCR rates in eTNBC pts treated with NACT +\- IO? Here to answer my amazing friend (and collegue) @RobertoBuonaiu3 at his first #SABCS23 poster presentation. 🔥🇺🇸
Excited to share our work in #SABCS23 regarding the impact of chemotherapy relative dose intensity (RDI) on pCR in TNBC pts treated with NACT +\- pembrolizumab. RDI indipendently predicts pCR. Additionally our data suggest that RDI may be associated with improved EFS.
0
2
4
Another data confirming the importance of agnostic approach in rare cancers with limited therapeutic options.
The #STATICE phase 2 trial of T-DXd for HER2-expressing uterine carcinosarcoma is out on JCO. Of 32 patients receiving T-DXd, both HER2-high & HER2-low pts achieved ORR>50%. Impressive activity for a rare, but very aggressive disease. High ILD rate (27%). https://t.co/TSgsbxhkha
0
1
1
Agnostic approach… is it the key for rare cancers?
@CancerRevengers @curecc @CCA_Alliance @CholangioNet @Cholangiocarci2 @BenWestphalen @JavleMilind @OncBrothers @mtmdphd @marklewismd @GraceCordovano Yes. For pediatric tumors, tumors that are being explored for HER2➕include Osteosarcoma, Malignant Rhabdoid Tumor, and Wilms tumor. Trials are now open across tumor types. The other older name is DS-8201 or T-DXd. Open on ClinicalTrials▪️gov. https://t.co/kerRZIE8No
0
1
3
🌀
0
0
3
Organ infiltration degree and prognosis in primary #retroperitoneal #liposarcoma is now published on @AnnSurgOncol
https://t.co/8YBA3wsiWB Percentage of some degree of organ involvment is close to 90% regardless of the liposarcoma subtype (equal in WD and DD variants).
3
34
63
Two parallel non-rand ph 2 trials of olaparib that included 46 pretreated pts w adv pancreatic cancer w BRCAness showed disease ctrl rate 74%, med PFS 3.7 mo, med OS 9.9 mo https://t.co/JMAT84g9UM
#GICSM
0
7
12